BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

BioNTech SENASDAQ: BNTX

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income grows, but more slowly than its trailing trend

Q2 FY2026 net income of €834.39M (cash outflow) rose 90.3% year over year, behind the +348.2% change in trailing-twelve-month net income. Sequentially, it rose 54.3% from the prior quarter.

Context

  • Net income amounted to 39.6% of revenue in FY2025, up 15.0 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 11 analysts of -€1.37B (+26.0%) for the fiscal year ending Dec 2026, a slowdown from the +61.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-€834.39M+54.3% QoQ
Last fiscal yearDec 2025
-€1.09B+61.0% YoY
LTMJun 2026
-€1.71B+348.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+90.3%+611.3%+521.1 pp
1 year+61.0%+26.0%-35.0 pp
3-year CAGR—-3.7%—
5-year CAGR-13.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(1.09B) EUR
Year-over-year change
-61.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +348.2% is the 2nd highest of 9, against a peer median of +27.4%.
  • Net income amounts to 64.7% of revenue for BNTX, versus a peer median of 46.7%.
BNTX Competitors
Net Income for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
INCYIncyte CorporationLTM Jun 2026$1.61B USD+85.1%+55.7%27.7%
IBRXImmunityBio, Inc.LTM Sep 2026$1.11B USD+218.3%-5.5%607.8%
GMABGenmab A/SLTM Jun 2026$861.1M USD—-48.4%20.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$220.54M USD-44.5%-0.4%58.2%
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
TGTXTG Therapeutics, Inc.LTM Sep 2026$106.06M USD-76.3%—11.8%
XNCRXencor, Inc.LTM Jun 2026$71.19M USD-60.8%+18.5%67.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
IMCRImmunocore Holdings plcLTM Mar 2026$27.59M USD+28.8%-20.5%7.2%
Peer median (excluding BNTX) —+27.4%-5.5%46.7%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.05B12.95B1.19B(677.7M)(1.09B)
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
Deferred Income Tax000070.98M
Stock-Based Compensation93.9M108.6M51.4M100.9M0
Change in Working Capital(10.73B)4.52B5.57B1.22B516.57M
Accounts Receivables(11.81B)4.37B5.37B387.7M1.04B
Inventory(438.4M)62.9M81.9M74.5M170.88M
Accounts Payables1.52B85.7M118.9M758.4M(695.23M)
Other Working Capital00000
Other Non-Cash Items(3.6B)(4.13B)(1.62B)(734.1M)574.01M
Operating Cash Flow889.7M13.58B5.37B207.7M438M
Capital Expenditures(154M)(363.3M)(705.5M)(452.3M)(168.19M)
Acquisitions (Net)(20.8M)0(336.9M)0183.27M
Purchases of Investments(394.7M)(47.8M)(6.98B)(12.37B)(10.97B)
Sales of Investments0375.2M1.19B10.74B9.14B
Other Investing Activities(23.1M)(33.5M)(576.59M)(164.6M)0
Investing Cash Flow(566.1M)(35.3M)(6.95B)(2.08B)(2.37B)
Debt Repayment(66.7M)(59.1M)(40.1M)(45.9M)(10.85M)
Common Stock Issued160.9M110.5M000
Common Stock Repurchased0(986.4M)(738.5M)00
Dividends Paid0(484.3M)000
Other Financing Activities0000(39.96M)
Financing Cash Flow94.2M(1.42B)(778.6M)(45.9M)(50.81M)
Effect of Forex Changes64.7M60.1M150.3M14.8M1.05B
Net Change in Cash482.5M12.18B(2.21B)(1.9B)(931.17M)
Free Cash Flow735.7M13.21B4.67B(244.6M)269.81M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.